Reduction-responsive and tumor-targeted polyprodrug nanocarriers for targeting therapy of hepatocellular carcinoma

Abstract

Nanotechnology in cancer therapy increases medication bioavailability and lowers systemic toxicity. Additionally, polyprodrug delivery systems provide higher drug-carrying capacity and biosafety than traditional nano-drug delivery techniques. Nevertheless, the majority of...